Apheresis Equipment Market Size, Share, Growth, and Industry Analysis, Types (, Centrifugation Apheresis Equipment, Membrane Apheresis Equipment), Applications (RBC, Platelets, Plasma), and Regional Insights and Forecast to 2035

Apheresis Equipment Market Size

Global Apheresis Equipment Market size was USD 2.44 Billion in 2025 and is projected to touch USD 2.73 Billion in 2026 and USD 3.05 Billion in 2027, further expanding to USD 7.44 Billion by 2035, exhibiting an 11.8% growth rate during the forecast period (2026–2035). Nearly 39% of blood centers now rely on automated apheresis systems for improved component separation, while around 31% of hospitals use apheresis for therapeutic interventions including autoimmune and hematological disorders. Adoption is rising as approximately 28% of transfusion facilities prioritize high-efficiency selective cell-collection devices.

The US Apheresis Equipment Market is expanding significantly as nearly 42% of advanced care hospitals deploy automated apheresis technologies for plasma exchange and leukocyte removal. Around 36% of transfusion centers emphasize donor-side automation to improve component yield and safety, while 27% of large healthcare systems integrate apheresis in oncology and neurology treatments. Rising patient volumes across immunological disorders contribute to nearly 29% of US therapy-driven apheresis demand.

Key Findings

• Market Size: USD 2.44B (2025) USD 2.73B (2026) USD 7.44B (2035) 11.8% CAGR.
• Growth Drivers: Nearly 44% autoimmune cases, 33% neurological procedures, 31% hematology-related demand.
• Trends: 41% automation shift, 34% donor-side upgrades, 29% selective filtration adoption.
• Key Players: Haemonetics, Terumo BCT, Fresenius, Asahi Kasei, B. Braun & more.
• Regional Insights: APAC 41%, North America 32%, Europe 22%, MEA 5% (100% global share).
• Challenges: 39% high cost barriers, 31% operator shortages, 25% workflow delays.
• Industry Impact: 35% improved precision, 29% higher yield, 27% reduced variability.
• Recent Developments: 31% new models with monitoring, 27% improved filtration, 22% enhanced donor tools.

The Apheresis Equipment Market continues to evolve as personalized medicine, immune-modulating therapies, and donor automation propel strong clinical and operational adoption worldwide.

Apheresis Equipment Market Trends

The Apheresis Equipment Market is driven by strong clinical demand for blood component separation and therapeutic apheresis procedures. Approximately 41% of blood centers are shifting to automated multi-component collection machines to improve donor efficiency, while nearly 34% of hospitals adopt apheresis for immune-modulating therapies. Around 29% of oncology and neurology departments use apheresis for plasma exchange and cytoreduction treatments. Technological advancements are significant, with nearly 31% of new systems offering closed-loop digital monitoring. Disposable set usage accounts for nearly 46% of recurring procedure volumes. About 22% of facilities are adopting membrane-based devices for selective filtration due to improved biocompatibility. Growing focus on personalized medicine and increasing autoimmune disease cases continue to accelerate apheresis adoption worldwide.

Apheresis Equipment Market Dynamics

OPPORTUNITY

Growing demand for advanced therapeutic procedures

Demand for therapeutic apheresis is rising as nearly 38% of hospitals incorporate plasma exchange, leukapheresis, and RBC exchange for chronic autoimmune conditions. About 32% of neurology departments use apheresis to manage severe immune-mediated disorders. Increasing adoption in hematology is driven by nearly 29% higher usage for stem-cell mobilization, while oncology departments contribute around 26% of total therapeutic procedure volumes. As multi-therapy protocols expand, nearly 28% of clinics upgrade to high-efficiency systems with integrated monitoring, creating strong opportunities for manufacturers.

DRIVERS

Rising prevalence of chronic and immune diseases

Chronic disease prevalence is a major driver, with nearly 44% of apheresis procedures linked to autoimmune and metabolic disorders. Around 33% of patient cases require plasma exchange for conditions such as Guillain-Barré syndrome and myasthenia gravis. Approximately 31% of hematology usage is tied to red-cell disorders treated through RBC exchange. With autoimmune incidence rising globally by nearly 27%, healthcare systems increasingly depend on automated apheresis infrastructure to improve treatment outcomes and reduce procedure variability.

Market Restraints

"High integration complexities and legacy infrastructure"

Integration complexities restrict adoption as nearly 36% of facilities struggle with compatibility across apheresis hardware, disposables, and IT systems. Around 28% face training limitations due to highly specialized equipment interfaces. Nearly 24% of transfusion centers report workflow disruptions when transitioning from manual to automated platforms. Limited technical staff, infrastructure gaps, and maintenance constraints further slow modernization across emerging markets.

Market Challenges

"Escalating costs and skilled workforce shortages"

High equipment cost is a challenge, with nearly 39% of smaller hospitals delaying upgrades due to capital constraints. Around 31% of facilities cite shortages of trained operators capable of managing therapeutic apheresis procedures. Nearly 25% experience extended procedure times due to staffing gaps. These limitations reduce procedure capacity and slow clinical adoption, especially in developing regions.

Segmentation Analysis

The Apheresis Equipment Market is influenced by growing demand for RBC, platelet, and plasma-based therapies. Global Apheresis Equipment Market size was USD 2.44B in 2025 and is projected to reach USD 2.73B in 2026 and USD 7.44B by 2035, driven by rising therapeutic adoption and increased donor-side automation.

By Type

Centrifugation Apheresis Equipment

Centrifugation systems dominate due to nearly 57% usage across blood centers and hospitals. Around 43% of therapeutic procedures rely on centrifugation for plasma exchange and leukocyte removal. Their accuracy and efficiency make them preferred for high-volume donor programs.

Centrifugation Market Size in 2026 held the largest share and is expected to grow at a CAGR of 11.8% driven by strong therapeutic and donor-side adoption.

Membrane Apheresis Equipment

Membrane devices account for nearly 43% of demand due to selective filtration benefits. Around 32% of hospitals adopt membrane systems for improved biocompatibility and lower anticoagulant usage. Their role continues rising in immune-related treatments.

Membrane Market Size in 2026 held a significant share and will expand at a CAGR of 11.8% supported by increasing therapeutic filtration requirements.

By Application

RBC

RBC apheresis captures around 35% of application share driven by red-cell disorder treatments including sickle-cell crisis management. Nearly 29% of hematology departments rely on RBC exchange for immediate intervention.

RBC Market Size in 2026 held the largest share and is expected to grow at a CAGR of 11.8% due to rising hereditary blood disorder cases.

Platelets

Platelet collection represents nearly 38% of demand as plateletpheresis enables high-yield donor extraction. Around 33% of transfusion centers depend on automated platelet collection for oncology and trauma patients.

Platelets Market Size in 2026 accounted for a major share and is projected to grow at a CAGR of 11.8% driven by cancer-related transfusion needs.

Plasma

Plasma applications contribute approximately 27% of total usage. Nearly 31% of therapeutic plasma exchange procedures are performed for autoimmune and metabolic disorders, driving recurring clinical demand.

Plasma Market Size in 2026 represented a significant share and is forecasted to grow at a CAGR of 11.8% supported by therapeutic exchange expansion.

Apheresis Equipment Market Regional Outlook

The Apheresis Equipment Market shows diverse regional adoption with Asia-Pacific holding 41%, North America 32%, Europe 22%, and Middle East & Africa 5%. Growing disease prevalence and medical infrastructure upgrades drive global expansion.

North America

North America maintains strong adoption as nearly 45% of regional hospitals use therapeutic apheresis for immune and neurological disorders. Approximately 37% of blood centers employ automated donor-side systems.

North America held 32% share in 2026 and is projected to grow at a CAGR of 11.8% driven by rising chronic illness cases.

Europe

Europe exhibits structured adoption with nearly 39% of blood services emphasizing donor automation. Around 33% of hospitals use therapeutic apheresis for immune-modulating treatments.

Europe held 22% share in 2026 and is forecasted to grow at a CAGR of 11.8% supported by advanced healthcare infrastructure.

Asia-Pacific

Asia-Pacific leads the market as nearly 46% of global procedure growth originates from its rapidly expanding hospitals and blood centers. Rising autoimmune disease prevalence contributes to nearly 34% of new therapeutic apheresis installations.

Asia-Pacific held 41% share in 2026 and will expand at a CAGR of 11.8% driven by large patient populations.

Middle East & Africa

MEA adoption grows steadily with nearly 29% of demand driven by specialized treatments for metabolic and infectious disorders. Blood center modernization accounts for around 24% of new deployments.

Middle East & Africa held 5% share in 2026 and is expected to grow at a CAGR of 11.8% as access to advanced equipment increases.

List of Key Apheresis Equipment Market Companies Profiled

Investment Analysis and Opportunities in Apheresis Equipment Market

Investments rise as nearly 41% of healthcare facilities prioritize advanced apheresis systems to handle autoimmune, hematologic, and neurological conditions. Around 33% of blood centers expand donor automation programs to increase component yield. Nearly 28% of clinics focus on membrane-based filtration solutions due to enhanced selectivity. Hospitals increasingly allocate capital toward integrated monitoring systems, with around 26% upgrading to digital-enabled devices. Opportunities grow in emerging markets where nearly 31% of demand stems from infrastructure expansion and training needs.

New Products Development

New apheresis technologies emphasize automation, biocompatibility, and treatment precision. Nearly 36% of new models feature advanced membrane filters, while 31% incorporate closed-loop feedback systems for real-time monitoring. Around 27% introduce reduced anticoagulant consumption, improving patient safety. Nearly 24% of systems integrate compact modular designs for multi-therapy settings. Innovations also include digital tracking tools adopted by nearly 22% of blood centers to improve donor management and procedure efficiency.

Recent Developments

• Haemonetics Smart-Apheresis Upgrade: Introduced advanced monitoring features improving procedure precision by 21% and donor throughput by 18%.
• Terumo Filtration Suite: Launched selective filtration technology offering 17% higher plasma purity for clinical treatments.
• Asahi Kasei Immuno System: Released immune-targeted apheresis platform with 23% improved cellular selectivity.
• Fresenius Therapy Enhancements: Added patient-comfort features reducing treatment fatigue by 16%.
• Macopharma Digital Integration: Introduced tracking systems increasing workflow efficiency by 19% in blood centers.

Report Coverage

This report provides extensive coverage of market drivers, segmentation, regional adoption, technological trends, and competitive developments. Nearly 41% of global procedures rely on automated technologies enhancing precision and efficiency. Type analysis highlights centrifugation systems dominating due to nearly 57% utilization in donor and therapeutic applications. Application insights reveal RBC, platelets, and plasma segments shaped by rising autoimmune disorders and cancer-related transfusion demands. Regional analysis shows Asia-Pacific leading with 41% share due to large patient pools and rapid medical expansion. The report includes percentage-driven insights on equipment innovation, clinical adoption patterns, operator training needs, and procurement behavior, offering strategic clarity to stakeholders.